[Gastric Neuroendocrine Tumors. Endoscopic and Surgical Treatment]

Overview

Journal Chirurg

Specialty General Surgery

Date 2011 Jun 22

PMID 21691871

Citations 2

Authors

M B Niederle

B Niederle

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) of the stomach are the most frequent among all neuroendocrine neoplasms in the digestive tract. The diagnosis and classification are complicated by the fact that these tumors have to be categorized not only by common staging and grading but also according to their pathophysiological background (types). The types differ in their biological behaviour (aggressiveness) which influences therapeutic concepts. This article explains and summarizes the etiology and classification of gastric NETs and offers a precise concept for diagnosis and treatment to improve clinical outcome.

Citing Articles

Correlation between clinicopathological characteristics and the clinical prognosis of patients with gastroenteropancreatic neuroendocrine tumors.

Fan D, Li X, Yu Y, Wang X, Fang J, Huang C Mol Clin Oncol. 2023; 19(5):85.

PMID: 37809346 PMC: 10557094. DOI: 10.3892/mco.2023.2681.

[Surgical approach of gastroduodenal neuroendocrine neoplasms].

Fendrich V, Bartsch D Chirurg. 2016; 87(4):280-7.

PMID: 26779647 DOI: 10.1007/s00104-015-0138-1.

References

Eckhauser F, Lloyd R, Thompson N, Raper S, Vinik A . Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery. 1988; 104(6):1046-53. View

Guillem P . [Gastric carcinoid tumours. Is there a place for antrectomy?]. Ann Chir. 2005; 130(5):323-6. DOI: 10.1016/j.anchir.2005.03.010. View

Bordi C, Falchetti A, Azzoni C, DAdda T, Canavese G, Guariglia A . Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol. 1997; 21(9):1075-82. DOI: 10.1097/00000478-199709000-00012. View

Dakin G, Warner R, Pomp A, Salky B, Inabnet W . Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006; 93(5):368-72. DOI: 10.1002/jso.20468. View

Shimoyama S, Fujishiro M, Takazawa Y . Successful type-oriented endoscopic resection for gastric carcinoid tumors: A case report. World J Gastrointest Endosc. 2010; 2(12):408-12. PMC: 3010472. DOI: 10.4253/wjge.v2.i12.408. View

Hopper A, Bourke M, Hourigan L, Tran K, Moss A, Swan M . En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy. J Gastroenterol Hepatol. 2009; 24(9):1516-21. DOI: 10.1111/j.1440-1746.2009.05909.x. View

Reubi J . Peptide receptor expression in GEP-NET. Virchows Arch. 2007; 451 Suppl 1:S47-50. DOI: 10.1007/s00428-007-0443-2. View

Solcia E, Rindi G, Buffa R, Fiocca R, Capella C . Gastric endocrine cells: types, function and growth. Regul Pept. 2000; 93(1-3):31-5. DOI: 10.1016/s0167-0115(00)00175-0. View

Berna M, Annibale B, Marignani M, Luong T, Corleto V, Pace A . A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008; 93(5):1582-91. PMC: 2386679. DOI: 10.1210/jc.2007-2279. View

10.

Niederle M, Niederle B . Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist. 2011; 16(5):602-13. PMC: 3228191. DOI: 10.1634/theoncologist.2011-0002. View

11.

Ahlman H, Kolby L, Lundell L, OLBE L, Wangberg B, Granerus G . Clinical management of gastric carcinoid tumors. Digestion. 1994; 55 Suppl 3:77-85. DOI: 10.1159/000201206. View

12.

Norton J, Melcher M, Gibril F, Jensen R . Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2005; 136(6):1267-74. DOI: 10.1016/j.surg.2004.06.057. View

13.

Kloppel G, Perren A, Heitz P . The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13-27. DOI: 10.1196/annals.1294.002. View

14.

Gladdy R, Strong V, Coit D, Allen P, Gerdes H, Shia J . Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009; 16(11):3154-60. DOI: 10.1245/s10434-009-0687-y. View

15.

Richards M, Gauger P, Thompson N, Giordano T . Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg. 2004; 28(7):652-8. DOI: 10.1007/s00268-004-7345-0. View

16.

Varas M, Gornals J, Pons C, Espinos J, Abad R, Lorente F . Usefulness of endoscopic ultrasonography (EUS) for selecting carcinoid tumors as candidates to endoscopic resection. Rev Esp Enferm Dig. 2010; 102(10):577-82. DOI: 10.4321/s1130-01082010001000002. View

17.

Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S . Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008; 159(4):475-82. DOI: 10.1530/EJE-08-0420. View

18.

Hoshino M, Omura N, Yano F, Tsuboi K, Matsumoto A, Yamamoto S . Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia. Hepatogastroenterology. 2010; 57(98):379-82. View

19.

Chen D, Zhao C, Lindstrom E, Hakanson R . Rat stomach ECL cells up-date of biology and physiology. Gen Pharmacol. 1999; 32(4):413-22. DOI: 10.1016/s0306-3623(98)00221-3. View

20.

Khuroo M, Khuroo M, Khuroo N . Treatment of type I gastric neuroendocrine tumors with somatostatin analogs. J Gastroenterol Hepatol. 2010; 25(3):548-54. DOI: 10.1111/j.1440-1746.2009.06131.x. View